ReviewAnnals of medicine2026
Harnessing
Review in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDISCUSSION: Key MIC adhesin complexes - including the lectin-based MIC1/4/6 complex and the transmembrane MIC2-M2AP complex - mediate glycan recognition, host cell attachment, moving junction formation, and gliding motility. Beyond invasion, MICs function as immunomodulators engaging Toll-like receptors (TLR2, TLR4, TLR11) to elicit pro-inflammatory responses while activating EGFR-Akt signaling to inhibit autophagy. The translational potential is substantial: MIC-based antigens enable sensitive serodiagnosis, differentiating acute from chronic infections. In contrast, MIC-based vaccines across multiple platforms demonstrate considerable protective efficacy in preclinical experimental models. Notably, the MIC1-3 knockout strain confers protection in sheep that is comparable to that of commercial vaccines; however, it is important to note that most supporting evidence remains at the preclinical stage and clinical validation in human populations is still required.
conclusionsMICs represent promising targets that bridge fundamental parasitology and clinical applications. Integration of MIC biology with translational strategies provides foundations for developing next-generation diagnostics and vaccines against toxoplasmosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.